longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Starling Oncology

STLN

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -21.17, within the reasonable range, cheaper than 54.55% of the time in the past 1 years, and the industry ranks 22/23, the industry Median 13.51.

-21.17xP/E
$6.35Stock price
$-0.30Earnings per share
-21.17xP/E
Stock price$6.35Earnings per share$-0.30

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-21.07x
Typical range
-21.88x–-20.44x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
Industry median 13.51x
05101520

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
Industry median 13.51x
0x10x20x30x40x50x
P/E ratio
Name/Symbol
ACHCUSAcadia Healthcare
-2.32x107.17%$2.61B
BKDUSBrookdale Senior Living
-18.75x102.39%$2.59B
SNDAUSSonida Senior Living
-12.46x14.93%$1.81B
SGRYUSSurgery Partners
-19.68x3.28%$1.74B
STLNUSStarling Oncology
-21.17x70.00%$647.17M
RNVAUSRennova Health, Inc.
----$40.55K
IVPRUSInspire Veterinary Partners, Inc.
-0.00x--$22.44K

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.